Kit Simpson to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Kit Simpson has written about Antiretroviral Therapy, Highly Active.
Connection Strength
1.272
-
Cost of treatment in a US commercially insured, HIV-1-infected population. PLoS One. 2014; 9(5):e98152.
Score: 0.447
-
Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Investig. 2007; 27(7):443-52.
Score: 0.267
-
Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004 Sep-Oct; 5(5):294-304.
Score: 0.228
-
Improving the Youth HIV Prevention and Care Cascades: Innovative Designs in the Adolescent Trials Network for HIV/AIDS Interventions. AIDS Patient Care STDS. 2019 09; 33(9):388-398.
Score: 0.161
-
Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies. Health Qual Life Outcomes. 2013 Mar 12; 11:42.
Score: 0.103
-
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007; 27(1):67-74.
Score: 0.067